856 reports of this reaction
6.6% of all ELETRIPTAN HYDROBROMIDE reports
#2 most reported adverse reaction
MIGRAINE is the #2 most commonly reported adverse reaction for ELETRIPTAN HYDROBROMIDE, manufactured by ROERIG. There are 856 FDA adverse event reports linking ELETRIPTAN HYDROBROMIDE to MIGRAINE. This represents approximately 6.6% of all 13,057 adverse event reports for this drug.
Patients taking ELETRIPTAN HYDROBROMIDE who experience migraine should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIGRAINE is moderately reported among ELETRIPTAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to migraine, the following adverse reactions have been reported for ELETRIPTAN HYDROBROMIDE:
The following drugs have also been linked to migraine in FDA adverse event reports:
MIGRAINE has been reported as an adverse event in 856 FDA reports for ELETRIPTAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIGRAINE accounts for approximately 6.6% of all adverse event reports for ELETRIPTAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience migraine while taking ELETRIPTAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.